Abstract
One-hundred and two patients with good risk myeloid leukemia (CML first chronic phase or AML first CR) were transplanted from HLA-related donors after conditioning with (n = 45) or without anti-thymocyte globulin (ATG) (n = 57). One graft failure was observed in the non-ATG and none in the ATG group. The median time to leukocyte engraftment (>1 × 109/l) was 16 (range 12–33) in the ATG group and 17 days (range 11–29) in the non-ATG group (NS) and for platelet engraftment (>20 × 109/l) 24 and 19 days (P = 0.002), respectively. Acute GVHD grade II–IV was observed in 47% of the non-ATG and in 20% of the ATG group (P = 0.004). Grade III/IV GVHD occurred in 7% of the ATG and in 32% of the non-ATG group (P = 0.002). Chronic GVHD was seen in 36% and 67% (P = 0.005), respectively. After a median follow-up of 48 months (range 2–128), the 5-year estimated OS is 66% (95% KI: 51–81%) for the ATG group and 59% (95% KI: 46–72%) for the non-ATG group (NS). The 5-year estimated DFS is 64% (95% KI: 50–78%) for ATG and 55% (95% KI: 43–67%) for the non-ATG regimen (NS). The 5-year probability of relapse was 5% in the ATG and 15% in the non-ATG group (NS). ATG as part of the conditioning regimen leads to a significant reduction in GVHD without increase of relapse in patients with myeloid leukemia after stem cell transplantation from HLA-related donors.
Similar content being viewed by others
References
Sullivan K, Weiden P, Storb R et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical sibling as treatment of acute and chronic leukemia Blood 1989 73: 170 178
Martin P, Hansen J, Torok-Storb B et al. Graft failure in patients receiving T cell depleted HLA-identical allogeneic marrow transplants Bone Marrow Transplant 1988 3: 445 456
Apperley J, Jones L, Hale G et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T cell depletion with CAMPATH-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse Bone Marrow Transplant 1986 1: 53 66
Champlin R, Ho W, Mitsuyasu R et al. Graft failure and leukaemia relapse following T lymphocyte-depleted bone marrow transplants: effect of intensification of immunosuppressive conditioning Transplant Proc 1987 19: 2616 2619
Goldman J, Gale R, Horowitz M et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T cell depletion Ann Intern Med 1988 108: 806 814
Marmont A, Horowitz M, Gale R et al. T cell depletion of HLA-identical transplants in leukemia Blood 1991 78: 2120 2130
Champlin R, Winston H, Gajewski J et al. Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation Blood 1990 76: 418 423
Verdonck L, Dekker A, De Gast G et al. Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft Blood 1994 83: 3090 3096
Naparstek E, Or R, Nagler A et al. T cell-depleted allogeneic bone marrow transplantation for acute leukaemia using CAMPATH-1 antibodies and post transplant administration of donors peripheral blood lymphocytes for prevention of relapse Br J Haematol 1995 89: 506 515
Bunjes D, Hertenstein B, Wiesneth M et al. In vivo/ex vivo T cell depletion reduces the morbidity of allogeneic transplantation in patients with acute leukaemias in first remission without increasing the risk of treatment failure: comparison with cyclosporin/methotrexate Bone Marrow Transplant 1995 15: 563 568
Heit W, Bunjes D, Wiesneth M et al. Ex vivo T cell depletion with the monoclonal antibody CAMPATH-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation Br J Haematol 1986 64: 479 486
Hale G, Zhang MJ, Bunjes D et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection Blood 1998 92: 4581 4590
Kröger N, Zabelina T, Krüger W et al. Anti-thymocyte-globulin as part of the preparative regimen prevents acute and chronic graft-versus-host disease (GVHD) in allogeneic stem cell transplantation from unrelated donors Ann Hematol 2001 80: 209 215
Finke J, Bertz H, Schmoor C et al. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti T cell globulin Br J Haematol 2000 11: 303 313
Zander AR, Zabelina T, Kröger N et al. Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow Bone Marrow Transplant 1999 23: 889 893
Aversa F, Terenzi A, Carotti A et al. Improved outcome with T cell-depleted bone marrow transplantation for acute leukemia J Clin Oncol 1999 17: 1545 1550
Papadopoulos EB, Carabasi MH, Castro-Malaspina H et al. T cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease Blood 1998 91: 1083 1090
Przepiorka KM, Weisdorf D, Martin P . 1994 Consensus Conference on acute GVHD-grading Bone Marrow Transplant 1995 15: 825 828
Bearman SI, Appelbaum FR, Buckner CD et al. Regimen related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 1988 6: 1562 1568
McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Intern Med 1993 118: 255 267
Storb R, Etzioni R, Anasetti C et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia Blood 1994 84: 941 949
Horstmann M, Stockschläder M, Krüger W et al. Cyclophosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia for marrow transplantation from HLA-matched siblings: preliminary results Ann Hematol 1995 71: 77 81
Baurmann H, Revillard JP, Bonnefoy-Berard N et al. Potent effect of ATG as part of the conditioning in matched unrelated donor (MUD) transplantation Blood 1998 92: (Suppl. 1) 290a
Kolb HJ, Holler E, Knabe H et al. Conditioning treatment with antithymocyte globulin (ATG) modifies graft-versus-host disease in recipients of marrow from unrelated donors Blood 1995 86:: (Suppl. 1) 952a
Young J, Papadopoulos E, Cunningham I et al. T cell depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission Blood 1992 79: 3380 3387
Barrett A, Mavroudis D, Tisdale J et al. T cell depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft versus leukemia effect Bone Marrow Transplant 1998 21: 543 551
Eiermann TH, Lembrecht P, Zander AR . Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients Bone Marrow Transplant 1999 23: 779 781
Remberger M, Svahn BM, Hentschke P et al. Effect on cytokine release, engraftment and GVHD of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation Bone Marrow Transplant 1999 23: (Suppl. 1) 268
Curtis R, Travis L, Rowlings P et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study Blood 1999 94: 2208 2216
Acknowledgements
We thank the staff of the BMT unit for providing excellent care of our patients and the medical technicians for their excellent work in the BMT laboratory.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kröger, N., Zabelina, T., Krüger, W. et al. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 29, 683–689 (2002). https://doi.org/10.1038/sj.bmt.1703530
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703530
- Springer Nature Limited
Keywords
This article is cited by
-
Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation
Annals of Hematology (2020)
-
Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation
Bone Marrow Transplantation (2015)
-
Preemptive administration of human αβ T cell receptor-targeting monoclonal antibody GZ-αβTCR potently abrogates aggressive graft-versus-host disease in vivo
Annals of Hematology (2015)
-
Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation
Bone Marrow Transplantation (2014)
-
Intensification of GVHD prophylaxis with low-dose ATG-F before allogeneic PBSC transplantation from HLA-identical siblings in adult patients with hematological malignancies: results from a retrospective analysis
Bone Marrow Transplantation (2012)